These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15555997)

  • 21. New agents in development for breast cancer.
    Gao XP; Liu F
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):68-74. PubMed ID: 17218855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic gene regulation in cancer.
    Ballestar E; Esteller M
    Adv Genet; 2008; 61():247-67. PubMed ID: 18282509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of proteasome inhibitors in oncology and autoimmune diseases.
    Bennett MK; Kirk CJ
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):616-25. PubMed ID: 18729013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein-protein interactions and cancer: small molecules going in for the kill.
    Arkin M
    Curr Opin Chem Biol; 2005 Jun; 9(3):317-24. PubMed ID: 15939335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.
    Marks PA; Breslow R
    Nat Biotechnol; 2007 Jan; 25(1):84-90. PubMed ID: 17211407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Function and targeting of G-quadruplexes.
    Wong HM; Payet L; Huppert JL
    Curr Opin Mol Ther; 2009 Apr; 11(2):146-55. PubMed ID: 19330720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New insights on oxidative stress in cancer.
    Visconti R; Grieco D
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):240-5. PubMed ID: 19333869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221.
    Creighton-Gutteridge M; Cardellina JH; Stephen AG; Rapisarda A; Uranchimeg B; Hite K; Denny WA; Shoemaker RH; Melillo G
    Clin Cancer Res; 2007 Feb; 13(3):1010-8. PubMed ID: 17289897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HDAC inhibitors: a potential new category of anti-tumor agents.
    Pan LN; Lu J; Huang B
    Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-covalent ligand/DNA interactions: minor groove binding agents.
    Nelson SM; Ferguson LR; Denny WA
    Mutat Res; 2007 Oct; 623(1-2):24-40. PubMed ID: 17507044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia.
    Zhu X; Asa SL; Ezzat S
    Clin Cancer Res; 2008 Apr; 14(7):1984-96. PubMed ID: 18381936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.
    Hoshino I; Matsubara H; Hanari N; Mori M; Nishimori T; Yoneyama Y; Akutsu Y; Sakata H; Matsushita K; Seki N; Ochiai T
    Clin Cancer Res; 2005 Nov; 11(21):7945-52. PubMed ID: 16278420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deoxyribozymes: cleaving a path to clinical trials.
    Dass CR
    Trends Pharmacol Sci; 2004 Aug; 25(8):395-7. PubMed ID: 15276705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting transcription factors by small compounds--Current strategies and future implications.
    Hagenbuchner J; Ausserlechner MJ
    Biochem Pharmacol; 2016 May; 107():1-13. PubMed ID: 26686579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcription factors and neoplasia: vistas in novel drug design.
    Karamouzis MV; Gorgoulis VG; Papavassiliou AG
    Clin Cancer Res; 2002 May; 8(5):949-61. PubMed ID: 12006506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reanalysis of cancer drugs: old drugs, new tricks.
    Vande Woude GF; Kelloff GJ; Ruddon RW; Koo HM; Sigman CC; Barrett JC; Day RW; Dicker AP; Kerbel RS; Parkinson DR; Slichenmyer WJ
    Clin Cancer Res; 2004 Jun; 10(11):3897-907. PubMed ID: 15173099
    [No Abstract]   [Full Text] [Related]  

  • 37. QC in antisense oligo synthesis.
    Agris PF; Smith S; Fu C; Simkins SG
    Nat Biotechnol; 2002 Sep; 20(9):871-2. PubMed ID: 12205500
    [No Abstract]   [Full Text] [Related]  

  • 38. Use of transcription factors as agents and targets for drug development.
    Smith LM; Birrer MJ
    Oncology (Williston Park); 1996 Oct; 10(10):1532-8; discussion 1541-2. PubMed ID: 8905845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-DNA interactions: new discoveries and possibilities for cancer treatment.
    Souhami RL
    Q J Med; 1994 Apr; 87(4):195-7. PubMed ID: 8208908
    [No Abstract]   [Full Text] [Related]  

  • 40. [Mechanisms of action of drug therapy of cancer].
    García G
    Gac Med Mex; 1972 Feb; 103(2):129-45. PubMed ID: 5022797
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.